Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | TIPARP | Q7Z3E1 | 8/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24640710 | 1.00 | DRD2 (0.34) | DRD2DRD3TIPARPAXLIRAK4 | |
| SCHEMBL24639390 | 0.89 | SOS1 (0.37) | DRD2DRD3TIPARPIRAK4GRM5 | |
| SCHEMBL24639244 | 0.82 | TIPARP (0.34) | TIPARPAXL | |
| SCHEMBL24639265 | 0.82 | TIPARP (0.34) | TIPARPAXL | |
| SCHEMBL24640209 | 0.82 | TIPARP (0.34) | TIPARPAXL | |
| SCHEMBL26958217 | 0.82 | TIPARP (0.34) | DRD2DRD3TIPARPIRAK4HRH3 | |
| SCHEMBL24640612 | 0.81 | AXL (0.36) | TIPARPAXLHRH3HRH4 | |
| SCHEMBL24639247 | 0.81 | TIPARP (0.35) | TIPARPAXLGRM5HRH3 | |
| SCHEMBL24639266 | 0.81 | TIPARP (0.35) | TIPARPAXLGRM5HRH3 | |
| SCHEMBL24639256 | 0.80 | AXL (0.36) | TIPARPAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022170974-A1 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-08-18 | — | — | WO | disclosed |